In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

Background Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

Most patients were able to stay with treatment once starting it, with retention rates of about 60% to 80% through 12 months (rituximab had the highest retention and IL-6 inhibitors the lowest).

The introduction of biologic agents, especially rituximab (RTX), a chimeric monoclonal antibody targeting CD20+ B cells, has revolutionized the treatment landscape. This review synthesized the current ...

The disease had progressed despite a favourable initial response to conventional treatment with intravenous immunoglobulin and cytotoxics. Treatment with rituximab induced a lasting clinical remission ...

JAK inhibitors were found to be either marginally more effective or as effective as biologic DMARDs in reducing pain in ...

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...